Blood Journal
Leading the way in experimental and clinical research in hematology

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

  1. Susan Branford,
  2. Zbigniew Rudzki,
  3. Sonya Walsh,
  4. Ian Parkinson,
  5. Andrew Grigg,
  6. Jeff Szer,
  7. Kerry Taylor,
  8. Richard Herrmann,
  9. John F. Seymour,
  10. Chris Arthur,
  11. David Joske,
  12. Kevin Lynch, and
  13. Tim Hughes
  1. From the Institute of Medical and Veterinary Science, Adelaide, South Australia; Royal Melbourne Hospital, Melbourne, Victoria; Mater Hospital, Brisbane, Queensland; Royal Perth Hospital, Perth, Western Australia; Peter MacCallum Cancer Institute, Melbourne, Victoria; Royal North Shore Hospital, Sydney, New South Wales; Sir Charles Gairdner Hospital, Perth, Western Australia; and Novartis Pharmaceuticals Australia, North Ryde, Sydney.

You do not have access to the full text of this article, the first page of the PDF of this article appears below.

PDF extract preview

To view this item, select one of the options below

If you already have a subscription, you may gain access using your ASH username and password.

Sign In for Institutional Administrators

If you are a Librarian or institutional account administrator you can use this link to manage your account and view usage reports.


Purchase Short-Term Access

Pay per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00.
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.

OpenAthens Users

Log in through your institution

Sign Up

Subscribe to the Journal - Subscribe to the print and/or online journal.

Access for Patients

Access for Patients - Patients desiring access should contact the journal.